Condition
Mesothelioma
Estimated Enrollment: 9
Age Group: 18 Years and older (Adult, Senior)
Gender: All
Study Type: Interventional
Study Design Allocation: Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment
Study ID Numbers: NL44330.000.14
Study First Received: January 30, 2015
Last Updated: March 17, 2015
Estimated Primary Completion Date: December 2015
Primary Outcome Measures:
The primary objective is to establish a tolerable dose of MesoCancerVac in patients with malignant mesothelioma|The secondary objective is the evaluation of an immune response after MesoCancerVac
Sponsors and Collaborators:
Erasmus Medical Center
Website Link: https://ClinicalTrials.gov/show/NCT02395679
